We leverage our proprietary kinase switch control inhibitor platform to develop of highly selective, potent small molecule drug candidates that directly inhibit activation of kinases implicated in the growth and spread of cancers. We currently retain global development and commercialization rights to all of the drug candidates in our pipeline.
|Pre-Clinical||Phase 1||Phase 1b/2||Phase 3||Global Rights|
|Ripretinib*: Broad Spectrum Inhibitor of KIT & PDGFRα|
|Gastrointestinal Stromal Tumors|
|Other Solid Tumors |
(includes Gliomas, NSCLC, & Sarcomas)
|Rebastinib: Selective Inhibitor of TIE2|
|Solid Tumors in Combination with paclitaxel|
(includes breast, ovarian & endometrial cancers)
|Solid Tumors in Combination with carboplatin|
(includes mesothelioma, ovarian & breast cancers)
|DCC-3014: Selective Inhibitor of CSF1R|
|Solid Tumors & Tenosynovial Giant Cell Tumors|
Ripretinib, rebastinib and DCC-3014 are investigational new drugs under development and are not approved for marketing by any health authorities.